What question did this study set out to answer?

To review the evolving clinical paradigm from treating elevated blood pressure based on fixed diagnostic thresholds to reducing total cardiovascular disease risk.

June 18, 2024HypertensionOpen Access

BP-lowering therapy provides CV benefits at lower baseline BP thresholds and in IHD or HF.

Q: What is the clinical evidence from this study?

Study design: Review. Population: Hypertension and Cardiovascular Disease. Intervention: Blood pressure-lowering medications.

Q: What does this research mean for the field?

Blood pressure-lowering medications provide cardiovascular disease risk reduction at lower pre-treatment blood pressure thresholds and in patients with ischemic heart disease or heart failure. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

View Full Paper

Ask AI

Bookmark

Design

Editorial

Key result

Blood pressure-lowering medications provide cardiovascular benefits at lower pre-treatment blood pressure thresholds and in patients with ischemic heart disease or heart failure.

Authors

CMCian P. McCarthy RJRod Jackson JMJohn W. McEvoy

Discussion

Member takes

Overview

May support risk-based BP-lowering beyond traditional thresholds in IHD/HF; leaves open need for RCTs before practice change.

Key Points

To review the evolving clinical paradigm from treating elevated blood pressure based on fixed diagnostic thresholds to reducing total cardiovascular disease risk.
Synthesized historical and contemporary clinical trials evaluating blood pressure treatment thresholds and targets.
Analyzed clinical trials assessing blood pressure-lowering agents, such as renin-angiotensin system inhibitors, in patients with ischemic heart disease and systolic heart failure.
Contemporary clinical trials show significant cardiovascular benefits from lower pre-treatment systolic blood pressure thresholds (e.g., ≥130 mm Hg) and intensive targets (e.g., <120 mm Hg).
Trials in populations with ischemic heart disease and heart failure demonstrate that blood pressure-lowering agents improve outcomes through mechanisms such as reverse left ventricular remodeling, even in non-hypertensive ranges.

PICO

Population

Hypertension and Cardiovascular Disease

Intervention / Comparator

Blood pressure-lowering medications

The text discusses the paradigm shift from treating hypertension based on strict blood pressure thresholds to utilizing blood pressure-lowering medications for overall cardiovascular disease risk reduction.

Cite This Study

McCarthy et al. (2024) conducted a review in Hypertension and Cardiovascular Disease. Blood pressure-lowering medications was evaluated. Blood pressure-lowering medications provide cardiovascular benefits at lower pre-treatment blood pressure thresholds and in patients with ischemic heart disease or heart failure.

synapsesocial.com/papers/6aaa29cb04e0d8bfdda4e2cf https://doi.org/10.1161/hypertensionaha.124.21722

View Full Paper

Ask AI

Bookmark

June 18, 2024HypertensionOpen Access

BP-lowering therapy provides CV benefits at lower baseline BP thresholds and in IHD or HF.

View Full Paper

Ask AI

Bookmark

Design

Editorial

Key result

Blood pressure-lowering medications provide cardiovascular benefits at lower pre-treatment blood pressure thresholds and in patients with ischemic heart disease or heart failure.

Authors

CMCian P. McCarthy RJRod Jackson JMJohn W. McEvoy

Discussion

Member takes

Overview

May support risk-based BP-lowering beyond traditional thresholds in IHD/HF; leaves open need for RCTs before practice change.

Key Points

To review the evolving clinical paradigm from treating elevated blood pressure based on fixed diagnostic thresholds to reducing total cardiovascular disease risk.
Synthesized historical and contemporary clinical trials evaluating blood pressure treatment thresholds and targets.
Analyzed clinical trials assessing blood pressure-lowering agents, such as renin-angiotensin system inhibitors, in patients with ischemic heart disease and systolic heart failure.
Contemporary clinical trials show significant cardiovascular benefits from lower pre-treatment systolic blood pressure thresholds (e.g., ≥130 mm Hg) and intensive targets (e.g., <120 mm Hg).
Trials in populations with ischemic heart disease and heart failure demonstrate that blood pressure-lowering agents improve outcomes through mechanisms such as reverse left ventricular remodeling, even in non-hypertensive ranges.

PICO

Population

Hypertension and Cardiovascular Disease

Intervention / Comparator

Blood pressure-lowering medications

Cite This Study

synapsesocial.com/papers/6aaa29cb04e0d8bfdda4e2cf https://doi.org/10.1161/hypertensionaha.124.21722

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark